Acute Myeloid Leukemia | Topics

The latest episode of the ASTCT Talks episode features John DiPersio, MD, PhD, on emerging therapies in the treatment of acute myeloid leukemia.

Clinical decision-making based on minimal residual disease may be associated with improved therapy satisfaction and optimized post-remission treatment for patients with intermediate-risk acute myeloid leukemia.

The risk of infection during induction chemotherapy decreased among patients with acute myeloid leukemia treated with romyelocel-L.